



RECEIVED

AUG 23 2002

TECH CENTER 1600/2900

1/4

SEQUENCE LISTING

<110> Variation Biotechnologies Inc.

<120> IMMUNOGENIC FORMULATION AND PROCESS FOR PREPARATION THEREOF

<130> PAT 568A-2

<140> US 10/072,084

<141> 2002-02-08

<150> US 09/414,484

<151> 1999-10-8

<150> US 60/103,642

<151> 1998-10-9

<160> 16

<170> PatentIn version 3.0

<210> 1

<211> 21

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 1

Cys Thr Asp Leu Lys Asn Ala Thr Asn Thr Asn Ser Ser Ser Ser Arg  
1 5 10 15

Met Met Met Glu Lys  
20

<210> 2

<211> 21

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 2

Phe Tyr Lys Leu Asp Ile Val Pro Ile Asp Asn Thr Thr Ser Ser Tyr  
1 5 10 15

Arg Leu Ile Asn Cys  
20

<210> 3

<211> 21

<212> PRT

<213> Human immunodeficiency virus type 1

COPY OF PAPERS  
ORIGINALLY FILED

---

&lt;400&gt; 3

Thr Ser Lys Ser Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr  
 1 5 10 15  
 Gly Asp Ile Gly Asp  
 20

&lt;210&gt; 4

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Human immunodeficiency virus type 1

&lt;400&gt; 4

Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn  
 1 5 10 15  
 Asn Thr Glu Gly Ser  
 20

&lt;210&gt; 5

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Human immunodeficiency virus type 1

&lt;400&gt; 5

Thr Arg Asp Gly Gly Asn Asn Asn Asn Glu Thr Glu Ile Phe Arg Pro  
 1 5 10 15  
 Gly Gly Gly Asp  
 20

&lt;210&gt; 6

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Hepatitis C virus

&lt;400&gt; 6

Ala Thr Thr Tyr Val Thr Gly Gly Ala Ala Ala Arg Ala Thr Ala Gly  
 1 5 10 15  
 Leu Ala Ser Leu Phe Ser Pro Gly  
 20

&lt;210&gt; 7

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Hepatitis C virus

&lt;400&gt; 7

Ile Ser Tyr Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro Tyr  
 1 5 10

&lt;210&gt; 8

&lt;211&gt; 21

&lt;212&gt; PRT

<213> Influenza A virus

<400> 8

Glu Thr Gly Lys Arg Gly Gly Lys Ser Ser Gly Ser Ser Tyr Pro Val  
 1 5 10 15  
 Leu Asn Val Ser Tyr  
 20

<210> 9

<211> 21

<212> PRT

<213> Influenza A virus

<400> 9

Lys Lys Gly Ser Val His His Pro Ser Thr Ile Thr Glu Gln Thr Ser  
 1 5 10 15  
 Leu Tyr Val Asn Ala  
 20

<210> 10

<211> 21

<212> PRT

<213> Influenza A virus

<400> 10

Asn Gly Leu Phe Ser Lys Glu Ser Pro Asn Asn Lys Asn Lys Asp Pro  
 1 5 10 15  
 Ile Asp Thr Cys Asp  
 20

<210> 11

<211> 21

<212> PRT

<213> Influenza A virus

<400> 11

Tyr Val Ser Val Ser Ser Arg Ile Ala Ser Arg Pro Lys Val Arg  
 1 5 10 15  
 Gly Gln Gly Asp Thr  
 20

<210> 12

<211> 28

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 12

Cys Thr Asn Val Asn Thr Asn Asn Thr Thr Asn Thr Thr Ser Ser Ser  
 1 5 10 15  
 Gly Gly Thr Met Glu Lys Gly Glu Met Lys Asn Cys  
 20 25

<210> 13  
 <211> 30  
 <212> PRT  
 <213> Human immunodeficiency virus type 1

<400> 13  
 Met Thr Thr Glu Leu Arg Asp Lys Lys Gln Lys Glu Tyr Ala Leu Phe  
 1 5 10 15  
 Tyr Arg Leu Asp Val Val Pro Ile Asp Asn Asn Ser Thr Ser  
 20 25 30

<210> 14  
 <211> 27  
 <212> PRT  
 <213> Human immunodeficiency virus type 1

<400> 14  
 Arg Lys Ser Ile Arg Ile Gly Pro Gly Gln Ala Phe Tyr Ala Thr Gly  
 1 5 10 15  
 Asp Ile Ile Gly Asp Ile Arg Gln Ala His Cys  
 20 25

<210> 15  
 <211> 24  
 <212> PRT  
 <213> Human immunodeficiency virus type 1

<400> 15  
 Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser  
 1 5 10 15  
 Asn Asn Thr Glu Gly Ser Asp Thr  
 20

<210> 16  
 <211> 15  
 <212> PRT  
 <213> Human immunodeficiency virus type 1

<400> 16  
 Gly Asn Asn Asn Ser Ser Asn Glu Ile Phe Arg Pro Gly Gly Gly  
 1 5 10 15